Sanofi Video Q&A: CFO Jérôme Contamine Comments on Q3 2011 Results

PARIS--(BUSINESS WIRE)-- Sanofi, a global and diversified healthcare leader, reports earnings for the third quarter of 2011. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on results and outlook.

Click to watch the video:
http://www.eurobusinessmedia.com/Sanofi-video-Q-A-CFO-Jerome-Contamine-comments-on-Q3-2011-results?utm_source=ceo-direct&utm_medium=bw

Topics covered in the interview include:

- Group Performance
- Emerging Markets
- Lantus®
- Genzyme
- Vaccines
- New Product Submissions
- 2011 Guidance

About Sanofi:

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Company website: www.sanofi.com



CONTACT:

Investor Relations:
Sébastien Martel, +33 1 53 77 45 45
[email protected]
or
Media Relations:
+33 1 53 77 45 02
[email protected],

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Diabetes  Veterinary

MEDIA:

Logo
 Logo

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.